Stuart Poulton's most recent trade in Karyopharm Therapeutics Inc was a trade of 888 Common Stock done . Disclosure was reported to the exchange on Sept. 12, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Karyopharm Therapeutics Inc | Stuart Poulton | EVP, Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Sep 2025 | 888 | 28,111 (0%) | 0% | 0 | Common Stock | |
| Karyopharm Therapeutics Inc | Stuart Poulton | EVP, Chief Development Officer | Sale of securities on an exchange or to another person at price $ 6.43 per share. | 12 Sep 2025 | 401 | 27,710 (0%) | 0% | 6.4 | 2,578 | Common Stock |
| Karyopharm Therapeutics Inc | Stuart Poulton | EVP, Chief Development Officer | Sale of securities on an exchange or to another person at price $ 4.37 per share. | 29 Jul 2025 | 191 | 27,223 (0%) | 0% | 4.4 | 835 | Common Stock |
| Karyopharm Therapeutics Inc | Stuart Poulton | EVP, Chief Development Officer | Sale of securities on an exchange or to another person at price $ 6.29 per share. | 04 Mar 2025 | 3,548 | 27,414 (0%) | 0% | 6.3 | 22,317 | Common Stock |
| Karyopharm Therapeutics Inc | Stuart Poulton | EVP, Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2025 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Karyopharm Therapeutics Inc | Stuart Poulton | EVP, Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2025 | 9,166 | 9,166 | - | - | Stock Option (right to buy) | |
| Karyopharm Therapeutics Inc | Stuart Poulton | EVP, Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2025 | 5,000 | 26,379 (0%) | 0% | 0 | Common Stock | |
| Karyopharm Therapeutics Inc | Stuart Poulton | EVP, Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2025 | 4,583 | 30,962 (0%) | 0% | 0 | Common Stock | |
| Karyopharm Therapeutics Inc | Stuart Poulton | EVP, Chief Development Officer | Sale of securities on an exchange or to another person at price $ 0.63 per share. | 18 Feb 2025 | 5,914 | 320,714 (0%) | 0% | 0.6 | 3,726 | Common Stock |
| Karyopharm Therapeutics Inc | Stuart Poulton | EVP, Chief Development Officer | Sale of securities on an exchange or to another person at price $ 1.06 per share. | 30 Jul 2024 | 2,883 | 326,628 (0%) | 0% | 1.1 | 3,056 | Common Stock |
| Karyopharm Therapeutics Inc | Stuart Poulton | EVP, Chief Development Officer | Sale of securities on an exchange or to another person at price $ 1.17 per share. | 29 Feb 2024 | 16,311 | 335,666 (0%) | 0% | 1.2 | 19,084 | Common |
| Karyopharm Therapeutics Inc | Stuart Poulton | EVP, Chief Development Officer | Sale of securities on an exchange or to another person at price $ 1.20 per share. | 29 Feb 2024 | 6,155 | 329,511 (0%) | 0% | 1.2 | 7,386 | Common |
| Karyopharm Therapeutics Inc | Stuart Poulton | EVP, Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2024 | 188,205 | 351,977 (0%) | 0% | 0 | Common Stock | |
| Karyopharm Therapeutics Inc | Stuart Poulton | EVP, Chief Development Officer | Sale of securities on an exchange or to another person at price $ 1.33 per share. | 15 Feb 2024 | 5,748 | 163,871 (0%) | 0% | 1.3 | 7,645 | Common Stock |
| Karyopharm Therapeutics Inc | Poulton Stuart | EVP, Chief Development Officer | Sale of securities on an exchange or to another person at price $ 1.40 per share. | 15 Feb 2024 | 99 | 163,772 (0%) | 0% | 1.4 | 139 | Common Stock |
| Karyopharm Therapeutics Inc | Stuart Poulton | EVP, Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2024 | 13,333 | 169,619 (0%) | 0% | 0 | Common Stock | |
| Karyopharm Therapeutics Inc | Stuart Poulton | EVP, Chief Development Officer | Sale of securities on an exchange or to another person at price $ 1.70 per share. | 28 Jul 2023 | 2,845 | 156,286 (0%) | 0% | 1.7 | 4,837 | Common Stock |
| Karyopharm Therapeutics Inc | Stuart Poulton | EVP, Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2023 | 95,000 | 159,131 (0%) | 0% | 0 | Common Stock | |
| Karyopharm Therapeutics Inc | Stuart Poulton | EVP, Chief Development Officer | Sale of securities on an exchange or to another person at price $ 3.19 per share. | 15 Feb 2023 | 5,665 | 64,335 (0%) | 0% | 3.2 | 18,071 | Common Stock |
| Karyopharm Therapeutics Inc | Stuart Poulton | EVP, Chief Development Officer | Sale of securities on an exchange or to another person at price $ 3.16 per share. | 15 Feb 2023 | 196 | 64,131 (0%) | 0% | 3.2 | 619 | Common Stock |
| Karyopharm Therapeutics Inc | Stuart Poulton | EVP, Chief Development Officer | Sale of securities on an exchange or to another person at price $ 3.25 per share. | 15 Feb 2023 | 8 | 64,327 (0%) | 0% | 3.3 | 26 | Common Stock |